DSM-FIRMENICH AG

DSM‑Firmenich AG names Richard Ridinger as new chairman and pushes a €500 m share‑repurchase plan to boost capital and shareholder value in nutrition, health and beauty.

DSM-Firmenich AG has reported a strong start to 2025, with robust sales and earnings growth, strategic moves to enhance shareholder value, and a continued focus on innovation in the fields of nutrition, health, and beauty.

DSM-Firmenich AG has made significant progress in its share repurchase program and is poised to capitalize on the growing probiotics market, which is expected to reach $102.1 billion by 2029.